Список литературы

[1] Серов В.Н. и др. Руководство по амбулаторно-поликлинической помощи в акушерстве и гинекологии//М.: ГЭОТАР-Медиа. - 2016., ГЭОТАР-Мед. Москва.

[2] Апгар Б.С., Броцман Г.Л., Шпицер М. Клиническая кольпоскопия. Практическое руководство//М.: Практическая медицина. - 2014. - Т. 384., Практическ. Москва.

[3] Роговская С.И., Липова Е.В. Шейка матки, влагалище, вульва//Физиология, патология, кольпоскопия, эстетическая коррекция: Руководство для практикующих врачей. - 2014. - С. 52 - 71.

[4] Сайт "Международная ассоциация по патологии шейки матки и кольпоскопии". URL: www.IFCPC.info/com.

[5] Короленкова Л.И., Ермилова В.Д. Зона трансформации шейки матки как объект канцерогенного действия вирусов папилломы человека при возникновении цервикальных интраэпителиальных неоплазий и инвазивного рака//Архив патологии. - 2011. - Т. 73. - N. 6.

[6] Короленкова Л.И. Цервикальные интраэпителиальные неоплазии и ранние формы рака шейки матки: клинико-морфологическая концепция цервикального канцерогенеза. - 2017. Москва.

[7] Эрозия, эктопия и эктропион шейки матки. РЦРЗ (Республиканский центр развития здравоохранения МЗ РК). Клинические протоколы МЗ РК - 2015. (Рекомендовано Экспертным советом РГП на ПВХ "Республиканский центр развития здравоохранения".

[8] Состояние онкологической помощи населению России в 2018 году. Под ред. Каприна А.Д., Старинского В.В., Петровой Г.В. МНИОИ им. П.А. Герцена филиал ФГБУ "НМИЦ радиологии" Минздрава России. 2019. 236 стр.

[9] Sanad A.S., Kamel H.H., Hasan M.M. Prevalence of cervical intraepithelial neoplasia (CIN) in patients attending Minia Maternity University Hospital//Archives of gynecology and obstetrics. - 2014. - T. 289. - N. 6. - С. 1211 - 1217., Jun., doi: 10.1007/s00404-013-3109-0.

[10] Benard V.B. et al. Population-based incidence rates of cervical intraepithelial neoplasia in the human papillomavirus vaccine era//JAMA oncology. - 2017. - T. 3. - N. 6. - С. 833 - 837., Jun., doi: 10.1001/jamaoncol.2016.3609.

[11] Shahida S.M. et al. Prevalence of Cervical Intraepithelial Neoplasia in four Upazila of Dhaka Division//Mymensingh medical journal: MMJ. - 2019. - T. 28. - N. 3. - С. 655., Jul.

[12] World Health Organization. Reproductive Health et al. Comprehensive cervical cancer control: a guide to essential practice. - World Health Organization, 2014.

[13] Darragh T.M. et al. The lower anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Path, Oct., doi: 10.5858/arpa.LGT200570.

[14] Saslow D. et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer//CA: a cancer journal for clinici, Jul., doi: 10.1097/LGT.0b013e31824ca9d5.

[15] Савельева Г.М. и др. Национальное руководство//Акушерство-М.: Гэотар-Медиа. - 2015.

[16] Massad L.S. et al. American Society for Colposcopy and Cervical Pathology Consensus Guidelines Conference. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors//J Low Genit Tract Dis. - 2, doi: 10.1097/LGT.0b013e318287d329.

[17] Wilt T.J., Harris R.P., Qaseem A. Screening for cancer: advice for high-value care from the American College of Physicians//Annals of internal medicine. - 2015. - T. 162. - N. 10. - С. 718 - 725., doi: 10.7326/M14-2326.

[18] Unim B. et al. Role of pap-test in cervical cancer prevention: a systematic review and meta-analysisBrigid Unim//European Journal of Public Health. - 2014. - T. 24. - N. suppl_2.

[19] Шабалова И.П., Касоян К.Т. Цитология жидкостная и традиционная при заболеваниях шейки матки//Цитологический атлас. - 2016.

[20] Galgano M.T. et al. Using biomarkers as objective standards in the diagnosis of cervical biopsies//The American journal of surgical pathology. - 2010. - T. 34. - N. 8. - С. 1077., doi: 10.1097/PAS.0b013e3181e8b2c4.

[21] Nayar R., Wilbur D.C. The pap test and Bethesda 2014//Acta cytologica. - 2015. - T. 59. - N. 2. - С. 121 - 132., doi: 10.1002/cncy.21521.

[22] Каприн А.Д. и др. Скрининг рака шейки матки - нерешенные проблемы//Research'n Practical Medicine Journal. - 2015. - T. 2. - N. 1.

[23] Сухих Г.Т. и др. Профилактика рака шейки матки. - 2012.

[24] Bak M. et al. Liquid-based cervical cytology ThinPrep screening in Hungary//Orvosi hetilap. - 2014. - T. 155. - N. 18. - С. 708 - 714., doi: 10.1556/OH.2014.29875.

[25] Artymuk N.V., Marochko K.V. Predictive value of different diagnostic methods for detection of cervical intraepithelial neoplasia and cervical cancer//Lietuvos akuserija ir ginekologija. - 2017. - T. 20. - N. 3. - С. 222 - 227.

[26] Royal College of Obstetricians and Gynaecologists: "Progress in Cervical Screening in the UK" Scientific Impact Paper No. 7.

[27] ACOG. Practice Bulletin No. 157 Summary: Cervical Cancer Screening and Prevention, Obstet. Gynecol., vol. 127, no. 1, pp. e1 - e20, Jan. 2016, doi: 10.1097/AOG.0000000000001263.

[28] Global Guidance For Cervical Cancer Prevention and Control October FIGO, 2009.

[29] Тимуш Э., Адамс К. Шейка матки. Цитологический атлас. Перевод с английского под редакцией Н.И. Кондрикова//Москва. - 2009. - С. 21.

[30] Новик В.И. и др. Оценка информативности цервикальных мазков при получении материала разными методами//Новости клин. цитологии России. - 2000. - N. 4. - С. 3 - 4.

[31] Yu L. et al. Diagnostic value of p16INK4A, Ki-67, and human papillomavirus L1 capsid protein immunochemical staining on cell blocks from residual liquid-based gynecologic cytology specimens//Cancer cytopathology. - 2010. - T. 118. - N. 1. - С. 47 - 55., doi: 10.1002/cncy.20061.

[32] Bonde J.H. et al. Clinical Utility of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Systematic Review//Journal of lower genital tract disease. - 2020. - T. 24. - N. 1. - С. 1 - 13.

[33] Workowski K.A., Bolan G.A. Sexually transmitted diseases treatment guidelines, 2015//MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports. - 2015. - T. 64. - N. RR-03. - С. 1.

[34] Shafi M.I. European quality standards for the treatment of cervical intraepithelial neoplasia (CIN). European Federation for Colposcopy. - 2007.

[35] Bzhalava D. Human papillomavirus reference clones//International Human Papillomavirus Reference Center. Available at: URL: http://www.hpvcenter.se/html/refclones.html, consulte en septembre. - 2014.

[36] World Health Organization et al. WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. 2013//Geneva. WHO. - 2015.

[37] Вакцины против папилломавирусной инфекции человека: документ по позиции ВОЗ., http://www.who.int/wer, no. 43, pp. 465 - 492, 2014.

[38] Комплексная борьба с раком шейки матки. Краткое практическое руководство. ВОЗ., p. 278, 2010.

[39] COTARCEA S. et al. The Importance of Ultrasound Monitoring of the Normal and Lesional Cervical Ectropion Treatment//Current health sciences journal. - 2016. - T. 42. - N. 2. - С. 188., doi: 10.12865/CHSJ.42.02.11.

[40] Del Priore G. et al. Oral diindolylmethane (DIM): pilot evaluation of a nonsurgical treatment for cervical dysplasia//Gynecologic oncology. - 2010. - T. 116. - N. 3. - С. 464 - 467., doi: 10.1016/j.ygyno.2009.10.060.

[41] Castanon A. et al. Effect of diindolylmethane supplementation on low-grade cervical cytological abnormalities: double-blind, randomised, controlled trial//British journal of cancer. - 2012. - T. 106. - N. 1. - С. 45., doi: 10.1038/bjc.2011.496.

[42] Белокриницкая Т.Е. и др. Проспективная оценка эффективности лечения цервикальных энтраэпителиальных неоплазий, ассоциированных с папилломавирусной инфекцией//Акушерство и гинекология. - 2016. - N. 4. - С. 86 - 93.

[43] Сухих Г.Т. и др. Исследование эффективности и безопасности препарата на основе дииндолметана у пациенток с цервикальной интраэпителиальной неоплазией (CIN 1 - 2).//Акушерство и гинекология. - 2018. N. 9.

[44] Ashrafian L. et al. Double-blind randomized placebo-controlled multicenter clinical trial (phase IIa) on diindolylmethane's efficacy and safety in the treatment of CIN: implications for cervical cancer prevention//EPMA Journal. - 2015. - T. 6. - N. 1. doi: 10.1186/s13167-015-0048-9.

[45] Castle P.E. et al. The clinical meaning of a cervical intraepithelial neoplasia grade 1 biopsy//Obstetrics and gynecology. - 2011. - T. 118. - N. 6. - С. 1222., doi: 10.1097/AOG.0b013e318237caf4.

[46] Cox J.T. et al. ASCUS-LSIL Triage Study (ALTS) Group. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directe, doi: 10.1067/mob.2003.461.

[47] Elit L. et al. Expectant management versus immediate treatment for low-grade cervical intraepithelial neoplasia: a randomized trial in Canada and Brazil//Cancer. - 2011. - T. 117. - N. 7. - С. 1438 - 1445., doi: 10.1002/cncr.25635.

[48] Jeronimo J. et al. Secondary prevention of cervical cancer: ASCO resource-stratified clinical practice guideline. J Glob Oncol. 2017; 3 (5): 635 - 57., doi: 10.1200/JGO.2016.006577.

[49] Santana B.N. et al. Cervical vaporization in LSIL and persistent HPV infection//Taiwanese Journal of Obstetrics and Gynecology. - 2018. - T. 57. - N. 4. - С. 475 - 478., doi: 10.1016/j.tjog.2018.06.010.

[50] P.P. Martin-Hirsch, Ed., Martin-Hirsch P.P.L. et al. Surgery for cervical intraepithelial neoplasia//Cochrane database of systematic reviews. - 2010. - N. 6., John Wiley & Sons, Ltd.

[51] van der Heijden E. et al. Follow-up strategies after treatment (large loop excision of the transformation zone (LLETZ)) for cervical intraepithelial neoplasia (CIN): Impact of human papillomavirus (HPV) test//Cochrane Database of Systematic Reviews. - 20, doi: 10.1002/14651858.CD010757.pub2.

[52] Schmidt D. et al. p16/ki-67 dual-stain cytology in the triage of ASCUS and LSIL papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study//Cancer cytopathology. - 2011. - T. 119. - N. 3. - С. 158 - 166., doi: 10.1002/cncy.20139.

[53] Yu L.L. et al. Evaluation of p16/Ki-67 dual staining in detection of cervical precancer and cancers: a multicenter study in China//Oncotarget. - 2016. - T. 7. - N. 16. - С. 21181., doi: 10.18632/oncotarget.8307.

[54] Peeters E. et al. Meta-analysis of the accuracy of p16 or p16/Ki-67 immunocytochemistry versus HPV testing for the detection of CIN2+/CIN3+ in triage of women with minor abnormal cytology//Cancer cytopathology. - 2019. - T. 127. - N. 3. - С. 169 - 180., doi: 10.1002/cncy.22103.

[55] Tanaka Y. et al. Predictors for recurrent/persistent high-grade intraepithelial lesions and cervical stenosis after therapeutic conization: a retrospective analysis of 522 cases//International journal of clinical oncology. - 2017. - T. 22. - N. 5. - С. 9, doi: 10.1007/s10147-017-1124-z.

[56] Ferris D. et al. Long-term study of a quadrivalent human papillomavirus vaccine//Pediatrics. - 2014. - T. 134. - N. 3. - С. e657-e665., doi: 10.1542/peds.2013-4144.

[57] Kew F.M., Cruickshank D.J. Routine follow-up after treatment for a gynecological cancer: a survey of practice//International Journal of Gynecologic Cancer. - 2006. - T. 16. - N. 1. - С. 380 - 384., doi: 10.1111/j.1525-1438.2006.00421.x.

[58] Минкина Г.Н. и др. Постлечебный мониторинг цервикальных интраэпителиальных неоплазий//Журнал акушерства и женских болезней. - 2011. - Т. 60. - N. 1.

[59] Nayar R., Wilbur D.C. The Bethesda System for reporting cervical cytology: a historical perspective//Acta cytologica. - 2017. - T. 61. - N. 4-5. - С. 359 - 372., doi: 10.1159/000477556.

[60] Meijer C. et al. Validation of high-risk HPV tests for primary cervical screening//Journal of Clinical Virology. - 2009. - T. 46. - С. S1-S4., doi: 10.1016/S1386-6532(09)00540-X.

[61] Szarewski A. et al. Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study//Journal of clinical microbiology. - 2012. - T. 50. - N. 6. - С. 1867 - 1873., Jun., doi: 10.1128/JCM.00181-12.

[62] Белокриницкая Т.Е. и др. Самостоятельный vs врачебный забор материала для ВПЧ-теста: результативность и приемлемость у пациенток разных возрастных групп Доктор//Доктор Ру. - 2017. - Т. 7. - N. 136. - С. 8 - 14.

[63] Белокриницкая Т.Е. и др. Результативность и приемлемость обследования на вирус папилломы человека при самостоятельном и врачебном заборе вагинального отделяемого//Акушерство и гинекология. - 2017. - N. 2. - С. 97 - 105.

[64] Артымук Н.В., Марочко К.В. Эффективность выявления вируса папилломы человека при помощи устройства для самостоятельного забора вагинального отделяемого//Акушерство и гинекология. - 2016. - N. 3. - С. 85 - 91.

[65] Баранов А.А. и др. Вакцинопрофилактика заболеваний, вызванных вирусом папилломы человека: позиции доказательной медицины. Обзор клинических рекомендаций//Вопросы современной педиатрии. - 2017. - Т. 16. - N. 2.

[66] National Advisory Committee on Immunization (NACI) et al. Updated Recommendations on Human Papillomavirus (HPV) Vaccines: 9-valent HPV vaccine 2-dose immunization schedule and the use of HPV vaccines in immunocompromised population. 2017. Ottawa//ON: Pub.

[67] National Advisory Committee on Immunization (NACI) et al. Updated Recommendations on Human Papillomavirus (HPV) Vaccines: 9-valent HPV vaccine and clarification of minimum intervals between doses in the HPV immunization schedule. 2016. Ottawa//ON: Public.

[68] The Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Guidelines for HPV vaccine. 2015.

[69] Global Advisory Committee on Vaccine Safety Statement on Safety of HPV vaccines - 17 December 2015., URL http//www.who.int/vaccine_safety/committee/topics/hpv/statement Dec 2015, 2015.

[70] ACOG. Committee Opinion No. 704: Human Papillomavirus Vaccination., Obstet. Gynecol., vol. 129, no. 6, pp. e173 - e178, Jun. 2017, doi: 10.1097/AOG.0000000000002052.

[71] Naud P.S. et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination//Human vaccines & immunotherapeutics. - 2014. - T. 10. - N. 8. - С., doi: 10.4161/hv.29532.

[72] Szarewski A. et al. Human papillomavirus testing by self-sampling: assessment of accuracy in an unsupervised clinical setting//Journal of Medical Screening. - 2007. - T. 14. - N. 1. - С. 34 - 42., doi: 10.1258/096914107780154486.

[73] Bhatla N. et al. Can human papillomavirus DNA testing of self-collected vaginal samples compare with physician-collected cervical samples and cytology for cervical cancer screening in developing countries?//Cancer epidemiology. - 2009. - T. 33. - N. 6. doi: 10.1016/j.canep.2009.10.013.

[74] Balasubramanian A. et al. Accuracy and cost-effectiveness of cervical cancer screening by high-risk HPV DNA testing of self-collected vaginal samples//Journal of lower genital tract disease. - 2010. - T. 14. - N. 3. - С. 185., doi: 10.1097/LGT.0b013e3181cd6d36.

[75] Boggan J.C. et al. Vaginal self-sampling for HPV infection as a primary cervical cancer screening tool in a Haitian population//Sexually transmitted diseases. - 2015. - T. 42. - N. 11. - С. 655., doi: 10.1097/OLQ.0000000000000345.

[76] Katki H.A. et al. Five-year risk of CIN3+ and cervical cancer for women with HPV-positive and HPV-negative high-grade Pap results//Journal of lower genital tract disease. - 2013. - T. 17. - N. 5 0 1. - С. S50., doi: 10.1097/LGT.0b013e3182854282.

[77] Keppler D., Lin A.W. (ed.). Cervical Cancer: Methods and Protocols. - Humana Press, 2015.

[78] Moore G. et al. LESSONS FROM PRACTICE: RISK OF CIN3 OR CANCER ASSOCIATED WITH AN LSIL OR HPV-POSITIVE ASC-US SCREENING RESULT IN WOMEN AGE 21 - 24//Journal of lower genital tract disease. - 2010. - T. 14. - N. 2. - С. 97., doi: 10.1097/LGT.0b013e3181b8b024.

[79] Polterauer S. et al. Cervical adenocarcinoma in situ: update and management//Current Obstetrics and Gynecology Reports. - 2013. - T. 2. - N. 2. - С. 86 - 93., doi: 10.1007/s13669-013-0039-6.